#BEGIN_DRUGCARD DB01230

# AHFS_Codes:
Not Available

# ATC_Codes:
N06BA05

# Absorption:
Pemoline is rapidly absorbed from the gastrointestinal tract

# Biotransformation:
Hepatic

# Brand_Mixtures:
Bebia Ointment Pommade (Magnesium Pemoline + Magnesium Silicate + Zinc Oxide)

# Brand_Names:
Azoksodon
Azoxodon
Azoxodone
Betanamin
Centramin
Constimol
Cylert
Cylert Chewable
Dantromin
Deltamine
Endolin
Fenoxazol
Fio
Hyton
Hyton asa
Juston-Wirkstoff
Kethamed
Myamin
NPL 1
Nitan
Notair
Okodon
PIO
Pemolin
Pemolina
Phenalone
Phenilone
Pioxol
Pomoline
Pondex
Ronyl
Senior
Sigmadyn
Sistra
Sistral
Stimul
Stimulol
Tradon
Tradone
Volital
Volitol
Yh 1

# CAS_Registry_Number:
2152-34-3

# ChEBI_ID:
Not Available

# Chemical_Formula:
C9H8N2O2

# Chemical_IUPAC_Name:
2-amino-5-phenyl-4,5-dihydro-1,3-oxazol-4-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
397520

# Description:
In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

# Dosage_Forms:
Tablet	Oral
Tablet, chewable	Oral

# Drug_Category:
Central Nervous System Stimulants

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Illicit
Small Molecule
Withdrawn

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Avoid high doses of caffeine.
Take without regard to meals. Avoid alcohol.

# GenBank_ID:
Not Available

# Generic_Name:
Pemoline

# HET_ID:
Not Available

# Half_Life:
The serum half-life of pemoline is approximately 12 hours.

# InChI_Identifier:
InChI=1S/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)

# InChI_Key:
InChIKey=NRNCYVBFPDDJNE-UHFFFAOYSA-N

# Indication:
For treatment of Attention Deficit Hyperactivity Disorder (ADHD)

# KEGG_Compound_ID:
C07899

# KEGG_Drug_ID:
D00744

# LIMS_Drug_ID:
1230

# Mechanism_Of_Action:
Not Available

# Melting_Point:
256 dec Â°C

# Molecular_Weight_Avg:
176.172

# Molecular_Weight_Mono:
176.05857751

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cyl1109.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450836

# Pharmacology:
Pemoline belongs to the group of medicines called central nervous system (CNS) stimulants. It is used to treat attention deficit hyperactivity disorder (ADHD). Pemoline stimulates the brain, probably by affecting neurotransmitters, the chemicals in the brain that nerves use to communicate with each other.

# Predicted_LogP_Hydrophobicity:
0.52

# Predicted_LogS:
-2.3

# Predicted_Water_Solubility:
9.79e-01 g/l

# Primary_Accession_No:
DB01230

# Protein_Binding:
Approximately 50% (bound to plasma proteins).

# PubChem_Compound_ID:
4723

# PubChem_Substance_ID:
46509085

# RxList_Link:
http://www.rxlist.com/cgi/generic/pemoline.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01169

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC(=O)C(O1)C1=CC=CC=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Pheniminooxazolidinone
Phenoxazole
Phenylisohydantoin
Phenylpseudohydantoin

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include insomnia, anorexia, stomach ache, skin rashes, increased irritability, mild depression, nausea, dizziness, headache, drowsiness, and hallucinations

# Update_Date:
2013-02-08 16:20:01 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Pemoline

# pKa_Isoelectric_Point:
Not Available

#END_DRUGCARD DB01230
